242 related articles for article (PubMed ID: 17050554)
21. Downregulation of estrogen receptor alpha and beta expression in carcinogen-induced mammary gland tumors of rats.
Kang JS; Jung NJ; Kim S; Kim DJ; Jang DD; Yang KH
Eksp Onkol; 2004 Mar; 26(1):31-5. PubMed ID: 15112577
[TBL] [Abstract][Full Text] [Related]
22. Decreased tumor formation in 7,12-dimethylbenzanthracene-treated stromelysin-1 transgenic mice is associated with alterations in mammary epithelial cell apoptosis.
Witty JP; Lempka T; Coffey RJ; Matrisian LM
Cancer Res; 1995 Apr; 55(7):1401-6. PubMed ID: 7882342
[TBL] [Abstract][Full Text] [Related]
23. Gene expression profiling of NMU-induced rat mammary tumors: cross species comparison with human breast cancer.
Chan MM; Lu X; Merchant FM; Iglehart JD; Miron PL
Carcinogenesis; 2005 Aug; 26(8):1343-53. PubMed ID: 15845649
[TBL] [Abstract][Full Text] [Related]
24. Reduced circulating insulin-like growth factor I levels delay the onset of chemically and genetically induced mammary tumors.
Wu Y; Cui K; Miyoshi K; Hennighausen L; Green JE; Setser J; LeRoith D; Yakar S
Cancer Res; 2003 Aug; 63(15):4384-8. PubMed ID: 12907608
[TBL] [Abstract][Full Text] [Related]
25. Modulation of p53 and c-myc in DMBA-induced mammary tumors by oral glutamine.
Todorova VK; Kaufmann Y; Luo S; Klimberg VS
Nutr Cancer; 2006; 54(2):263-73. PubMed ID: 16898871
[TBL] [Abstract][Full Text] [Related]
26. Gpx2 is an overexpressed gene in rat breast cancers induced by three different chemical carcinogens.
Naiki-Ito A; Asamoto M; Hokaiwado N; Takahashi S; Yamashita H; Tsuda H; Ogawa K; Shirai T
Cancer Res; 2007 Dec; 67(23):11353-8. PubMed ID: 18056462
[TBL] [Abstract][Full Text] [Related]
27. Cx43 suppresses mammary tumor metastasis to the lung in a Cx43 mutant mouse model of human disease.
Plante I; Stewart MK; Barr K; Allan AL; Laird DW
Oncogene; 2011 Apr; 30(14):1681-92. PubMed ID: 21151177
[TBL] [Abstract][Full Text] [Related]
28. A mammary-specific model demonstrates the role of the p53 tumor suppressor gene in tumor development.
Jerry DJ; Kittrell FS; Kuperwasser C; Laucirica R; Dickinson ES; Bonilla PJ; Butel JS; Medina D
Oncogene; 2000 Feb; 19(8):1052-8. PubMed ID: 10713689
[TBL] [Abstract][Full Text] [Related]
29. Targeted production of proprotein convertase PC1 enhances mammary development and tumorigenesis in transgenic mice.
Blanchard A; Iwasiow B; Yarmill A; Fresnosa A; Silha J; Myal Y; Murphy LC; Chrétien M; Seidah N; Shiu RP
Can J Physiol Pharmacol; 2009 Oct; 87(10):831-8. PubMed ID: 20052009
[TBL] [Abstract][Full Text] [Related]
30. Mutations in p53 are frequent in the preneoplastic stage of mouse mammary tumor development.
Jerry DJ; Ozbun MA; Kittrell FS; Lane DP; Medina D; Butel JS
Cancer Res; 1993 Jul; 53(14):3374-81. PubMed ID: 8324748
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of mammary gland tumors by short-term treatment of estradiol-3-benzoate associated with down-regulation of estrogen receptor ERalpha and ERbeta.
Kang JS; Kim S; Che JH; Nam KT; Kim DJ; Jang DD; Yang KH
Oncol Rep; 2004 Oct; 12(4):689-93. PubMed ID: 15375486
[TBL] [Abstract][Full Text] [Related]
32. NDF/heregulin induces persistence of terminal end buds and adenocarcinomas in the mammary glands of transgenic mice.
Krane IM; Leder P
Oncogene; 1996 Apr; 12(8):1781-8. PubMed ID: 8622899
[TBL] [Abstract][Full Text] [Related]
33. Oncogenic signaling pathways activated in DMBA-induced mouse mammary tumors.
Currier N; Solomon SE; Demicco EG; Chang DL; Farago M; Ying H; Dominguez I; Sonenshein GE; Cardiff RD; Xiao ZX; Sherr DH; Seldin DC
Toxicol Pathol; 2005; 33(6):726-37. PubMed ID: 16263698
[TBL] [Abstract][Full Text] [Related]
34. Role of ERalpha in the differential response of Stat5a loss in susceptibility to mammary preneoplasia and DMBA-induced carcinogenesis.
Miermont AM; Parrish AR; Furth PA
Carcinogenesis; 2010 Jun; 31(6):1124-31. PubMed ID: 20181624
[TBL] [Abstract][Full Text] [Related]
35. Human chorionic gonadotropin (hCG) up-regulates wnt5b and wnt7b in the mammary gland, and hCGbeta transgenic female mice present with mammary Gland tumors exhibiting characteristics of the Wnt/beta-catenin pathway activation.
Kuorelahti A; Rulli S; Huhtaniemi I; Poutanen M
Endocrinology; 2007 Aug; 148(8):3694-703. PubMed ID: 17510243
[TBL] [Abstract][Full Text] [Related]
36. Mammary cancer promotion by ovarian hormones involves IGFR/AKT/mTOR signaling.
Arumugam A; Parada J; Rajkumar L
Steroids; 2012 Jun; 77(7):791-7. PubMed ID: 22465879
[TBL] [Abstract][Full Text] [Related]
37. Overexpression of ligase defective E6-associated protein, E6-AP, results in mammary tumorigenesis.
Ramamoorthy S; Tufail R; Hokayem JE; Jorda M; Zhao W; Reis Z; Nawaz Z
Breast Cancer Res Treat; 2012 Feb; 132(1):97-108. PubMed ID: 21553290
[TBL] [Abstract][Full Text] [Related]
38. High Cks1 expression in transgenic and carcinogen-initiated mammary tumors is not always accompanied by reduction in p27Kip1.
Westbrook L; Ramanathan HN; Isayeva T; Mittal AR; Qu Z; Johnson MD; Kern FG; Ponnazhagan S; Grubbs CJ; Thottassery JV
Int J Oncol; 2009 May; 34(5):1425-31. PubMed ID: 19360356
[TBL] [Abstract][Full Text] [Related]
39. Prepubertal genistein exposure affects erbB2/Akt signal and reduces rat mammary tumorigenesis.
Peng JH; Zhu JD; Mi MT; Li FJ; Cai L; Dong JZ; Zhang HX; Zhao Y; Xue RL
Eur J Cancer Prev; 2010 Mar; 19(2):110-9. PubMed ID: 20051871
[TBL] [Abstract][Full Text] [Related]
40. Exploring the gain of function contribution of AKT to mammary tumorigenesis in mouse models.
Blanco-Aparicio C; Cañamero M; Cecilia Y; Pequeño B; Renner O; Ferrer I; Carnero A
PLoS One; 2010 Feb; 5(2):e9305. PubMed ID: 20174572
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
